Hydroxyurea Improves Oxygen Transport Effectiveness in Sickle Cell Anemia Patients
| العنوان: | Hydroxyurea Improves Oxygen Transport Effectiveness in Sickle Cell Anemia Patients |
|---|---|
| المؤلفون: | Russell E. Ware, Sheryl Nelson, Danielle Guffey, Charles G. Minard, Caroline Yappan, Bogdan Dinu, Vivien A. Sheehan |
| المصدر: | Blood. 124:2716-2716 |
| بيانات النشر: | American Society of Hematology, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | medicine.medical_specialty, education.field_of_study, Pathology, medicine.diagnostic_test, business.industry, Immunology, Population, Blood viscosity, Oxygen transport, Cell Biology, Hematology, Venous blood, Hematocrit, medicine.disease, Biochemistry, Gastroenterology, Sickle cell anemia, hemic and lymphatic diseases, Internal medicine, Fetal hemoglobin, medicine, education, business, Mean corpuscular volume |
| الوصف: | Background: Sickle cell disease (SCD) patients have altered blood rheology due to erythrocyte abnormalities, including increased aggregation and reduced deformability, which together affect microcirculatory blood flow and tissue perfusion. At equal hematocrit, sickle cell blood viscosity is increased compared to normal individuals. The hematocrit to viscosity ratio (HVR) is a measure of red blood cell (RBC) oxygen carrying capacity, and is reduced in SCD with clinical consequences related to altered blood flow and reduced tissue oxygenation. Erythrocyte transfusions reduce HVR at low shear rates that mimic venous circulation, and do not change HVR at high shear rates that mimic arterial blood flow. Hydroxyurea is a safe and effective therapy for SCD; however, its effects on sickle cell rheology and HVR have not been fully investigated. Evaluating the effects of hydroxyurea on viscosity is especially critical, before its use is extended widely to patients with cerebrovascular disease or genotypes with higher hematocrit and higher viscosity such as Hemoglobin SC (HbSC). Methods: To determine the effects of hydroxyurea on viscosity and HVR, we designed a prospective study to measure whole blood viscosity at 45 s-1 (low shear) and 225 s-1(high shear) rates in pediatric patients with SCD using a Brookfield cone and plate viscometer under oxygenated conditions. Venous blood samples (1-3mL) were collected in EDTA and analyzed no more than 4 hours after phlebotomy; samples were run in duplicate by persons blinded to the patient’s sickle genotype and treatment status. Laboratory values were obtained using an ADVIA hematology analyzer. Samples were analyzed from three non-overlapping cohorts of patients with SCD and HbAA individuals for comparison: untreated HbSS patients (n= 43), HbSS patients treated with hydroxyurea at maximum tolerated dose (n=98), untreated HbSC patients (n=53) and HbAA patients (n=19). Laboratory parameters that differed significantly among the SCD groups were analyzed by simple linear regression. Results: Patient characteristics and viscosity measurements are shown in the Table. Within the SCD population, the viscosity was lowest among the untreated HbSS patients, presumably due to their low hematocrit, while viscosity was higher in HbSS patients on hydroxyurea and HbSC patients. When the HVR was calculated for each group, no significant difference was identified between untreated HbSS and untreated HbSC patients. However, hydroxyurea treatment significantly increased HVR at both 45s-1 and 225 s-1 (p |
| تدمد: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood.v124.21.2716.2716 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::a25ed6a5c824c99d01dcfcfe07cd9a2f https://doi.org/10.1182/blood.v124.21.2716.2716 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi...........a25ed6a5c824c99d01dcfcfe07cd9a2f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15280020 00064971 |
|---|---|
| DOI: | 10.1182/blood.v124.21.2716.2716 |